Identification of novel Ras-cooperating oncogenes in *Drosophila melanogaster*: A RhoGEF/Rho-family/JNK pathway is a central driver of tumorigenesis


*, Cell Cycle and Development lab, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
§, Department of Anatomy and Cell Biology, University of Melbourne, Melbourne, Victoria, Australia
**, Cell Cycle and Cancer Genetics lab, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
§§, Breast Cancer Translational Research Laboratory (BCTL), Jules Bordet Institute, Brussels, Belgium
***, Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia
§§§, Department of Biological Sciences, Tokyo Metropolitan University, Tokyo, Japan

¹, Present address, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA

The first two authors contributed equally to this work.
Short running title: Cooperation of RhoGEF/Rho-family/JNK with Ras

Key words:

*Drosophila melanogaster*

cooperative tumorigenesis

oncogenic Ras

Rho-family

Jun Kinase

Corresponding author: Helena E. Richardson, Peter MacCallum Cancer Center, 7 St Andrews place, East Melbourne, 3002, Victoria, Australia. Ph= (613)96561466, Fax= (613)96561411, Helena.richardson@petermac.org
ABSTRACT

We have shown previously that mutations in the apico-basal cell polarity regulators cooperate with oncogenic Ras ($Ras^{ACT}$) to promote tumorigenesis in *Drosophila melanogaster* and mammalian cells. To identify novel genes that cooperate with $Ras^{ACT}$ in tumorigenesis, we carried out a genome-wide screen for genes that when overexpressed throughout the developing Drosophila eye, enhance $Ras^{ACT}$-driven hyperplasia. $Ras^{ACT}$-cooperating genes identified were *Rac1*, *Rho1*, *RhoGEF2*, *pbl*, *rib* and *east*, which encode cell morphology regulators. In a clonal setting, which reveals genes conferring a competitive advantage over wild-type cells, only *Rac1*, an activated allele of *Rho1* (*Rho1^{ACT}*), *RhoGEF2* and *pbl* cooperated with $Ras^{ACT}$, resulting in reduced differentiation and large invasive tumors. Expression of *RhoGEF2* or *Rac1* with $Ras^{ACT}$ upregulated Jun kinase (JNK) activity, and JNK upregulation was essential for cooperation. However, in the whole tissue system upregulation of JNK alone was not sufficient for cooperation with $Ras^{ACT}$, whilst in the clonal setting JNK upregulation was sufficient for $Ras^{ACT}$-mediated tumorigenesis. JNK upregulation was also sufficient to confer invasive growth of Ras$^{V12}$-expressing mammalian MCF10A breast epithelial cells. Consistent with this, HER2$^+$ human breast cancers (where human-epidermal-growth-factor-2 is overexpressed and Ras signaling upregulated) show a significant correlation with a signature representing JNK pathway activation. Moreover, our genetic analysis in Drosophila revealed that Rho1 and Rac are important for the cooperation of RhoGEF2 or Pbl over-expression, and of mutants in polarity regulators, Dlg and aPKC, with $Ras^{ACT}$ in the whole tissue context. Collectively our analysis reveals the importance of the RhoGEF/Rho-family/JNK pathway in cooperative tumorigenesis with $Ras^{ACT}$. 
INTRODUCTION

Cancer is a multi-step process, and transformation from a normal cell to an invasive/metastatic cancer has been considered to involve 6 steps: (1) activation of mitogen-signaling pathways to allow growth factor independence; (2) elimination of cell cycle inhibitors, (3) prevention of apoptosis, (4) promotion of invasion and metastasis, (5) acquiring unlimited replicative ability (upregulation of Telomerase) and (6) activation of angiogenesis (reviewed by Hanahan and Weinberg 2000). In addition, there is strong evidence that normal cells surrounding tumor cells (tumor microenvironment) can significantly affect the growth and development of the tumor and that the tumor and stroma (surrounding normal cells) evolve together in the development of the tumor (reviewed by Biselli and Radisky 2001). The vinegar fly, Drosophila melanogaster, presents an excellent genetically amenable system to model the first four of these cancer hallmarks, as well as the interaction of tumor cells with their microenvironment (reviewed by Brumby and Richardson 2003).

Genetic analyses in Drosophila, have revealed many genes that when deregulated induce or contribute to tumorigenesis. Drosophila tumor suppressors have been classed as hyperplastic (such as those of the Salvador/Warts/Hippo (SWH) pathway), which result in increased proliferation or survival but do not disrupt tissue structure or differentiation, or neoplastic (such as Dlg, Scrib and Lgl), which lead to loss of tissue structure, differentiation defects and failure to exit the cell cycle (reviewed by Brumby and Richardson 2005; Hariharan and Bilder 2006). Dlg, Scrib and Lgl act antagonistically to the apical polarity modules, the atypical protein kinase C (aPKC) and Crumbs (Crb) complexes, to regulate epithelial apico-basal cell polarity and limit proliferation (reviewed by Humbert et al. 2008). We have recently shown that deregulation of Lgl, aPKC or Crb promotes tissue growth without affecting cell polarity by deregulation of the SWH pathway (Grzeschik et al. 2010). However, homozygous mutant epithelial tissue from scrib, lgl or dlg mutant larvae that has lost apico-basal cell polarity shows all four hallmarks of cancer that can be modeled in the fly; the tissue continues to proliferate, does not die, fails
to differentiate and is capable of invasive behavior (BILDER et al. 2000; BILDER and PERRIMON 2000; GATEFF 1978; GATEFF and SCHNEIDERMAN 1969; WOODHOUSE et al. 1998).

By contrast, when scrib or lgl mutant tissue is generated in the context of wild-type tissue in the developing Drosophila eye using clonal analysis, it only exhibits some of the hallmarks of cancer. While both lgl and scrib mutant clones are unable to cease proliferation, showing increased expression of the key G1-S phase cell cycle regulator Cyclin E (KNOBLICH et al. 1994; RICHARDSON et al. 1995; RICHARDSON et al. 1993) and ectopic cell cycles, they are still capable of differentiation thereby preventing overgrowth (BRUMBY and RICHARDSON 2003; GRZESCHIK et al. 2007). In addition, scrib mutant cells are eliminated by JNK-mediated cell death that is induced by the surrounding wild-type tissue (BRUMBY and RICHARDSON 2003). However, when activated Ras or Notch oncogenes are expressed in scrib mutant clones, cell survival is dramatically increased and invasive/metastatic behavior is observed (BRUMBY and RICHARDSON 2003; PAGLIARINI and XU 2003). This includes the breakdown of the basement membrane and invasion/migration of mutant cells to distant sites. Thus scrib loss-of-function shows many hallmarks of cancer and exhibits the ability to cooperate with oncogenic Ras or Notch in tumor progression.

The cooperation of scrib loss-of-function with Ras\textsuperscript{ACT} and activated Notch (Notch\textsuperscript{intra} or Notch\textsuperscript{ACT}) in tumorigenesis most likely depends on the loss of cell polarity, as mutations in other apico-basal cell polarity regulators of the Scrib, aPKC or Crb complexes can also cooperate with oncogenic Ras in tumorigenesis in Drosophila eye epithelial tissues (PAGLIARINI and XU 2003). Furthermore, overexpression of Crb, which results in a loss of apico-basal cell polarity, cooperates with Ras\textsuperscript{ACT} in tumorigenesis (LEONG et al. 2009). One important factor that contributes to Ras\textsuperscript{ACT}-mediated cooperative tumorigenesis with scrib\textsuperscript{-}, revealed by our and other studies, is the Jun kinase (JNK) signaling pathway (BRUMBY and RICHARDSON 2003; IGAKI et al. 2006; LEONG et al. 2009; UHLIROVA...
and BOHANNAN 2006). Blocking JNK function in scrib Ras\(^{\text{ACT}}\) tumors re-establishes differentiation and reduces the tumor’s invasive properties. Down-regulation of the E-cadherin-\(\beta\)-catenin complex in apico-basal polarity mutants also contributes to tumorigenesis (IGAKI et al. 2006). Whether JNK activation and E-cadherin-\(\beta\)-catenin down-regulation are the only events downstream of apico-basal polarity mutants contributing to Ras\(^{\text{ACT}}\)-cooperative tumorigenesis is unclear. We envisioned that insight might be gained on the nature of other critical functions that are affected by loss of cell polarity for Ras\(^{\text{ACT}}\)-cooperative tumorigenesis, by identifying other genes that cooperate with oncogenic Ras. In this study, we present the results of a genetic screen to identify genes that when overexpressed enhance a Ras\(^{\text{ACT}}\)-induced hyperplastic eye phenotype. We identified key regulators of the actin cytoskeleton and cell morphology, including Rho1-family GTPases and RhoGEFs as Ras\(^{\text{ACT}}\)-cooperating genes. We show JNK pathway activation underlies the cooperation of these actin cytoskeletal regulators with Ras\(^{\text{ACT}}\). Moreover, we show that JNK and Ras signaling cooperate to promote invasive growth in normal human mammary epithelial cells and reveal by bioinformatics analysis that JNK signaling correlates with upregulation of Ras in human breast cancer. Our studies reveal a RhoGEF/Rho-family/JNK pathway as an important factor in oncogenic Ras mediated tumorigenesis.
MATERIALS AND METHODS

Fly stocks, conditions of culture, overexpression and clonal analysis: For the screening of GS lines, a recombinant of ey-GAL4 and UAS-Ras85D\textsubscript{V12} (ey>\textit{Ras}\textsuperscript{ACT}) was generated. Potential interacting GS lines, were retested against ey>\textit{Ras}\textsuperscript{ACT} and also to ey-GAL4 to assess the effect of expression of the gene alone on the adult eye. At least 50 progeny were analyzed for each cross and representative images are shown. All flies were raised on a standard cornmeal agar food at 25°C.

Validating transgenes used were: \textit{UAS-rib} (Deborah Andrew), \textit{UAS-Rho1\textsuperscript{CFP2a}} (GRECO et al. 2001), \textit{UAS-Rho1\textsuperscript{ACT}} (BILLUART et al. 2001), \textit{UAS-RhoGEF2} (Udo Hacker, (WIDMANN and DAHMANN 2009)), \textit{UAS-east} (WASSER and CHIA 2000), \textit{UAS-pbl-GFP\#3} and \textit{UAS-pbl-GFP\#8} (Robert Saint, (SOMERS and SAINT 2003)), \textit{UAS-Rac1} (LUO et al. 1994).

The MARCM (mosaic analysis with repressible cell marker) system (LEE and LUO 2001) with \textit{FRT82B}, \textit{ey-FLP} and \textit{UAS-GFP} (\textit{eyFLP1}, \textit{UASmCD8-GFP};\textit{Tub-GAL4 FRT82B Tub-GAL80}; (LEE and TREISMAN 2001)) was used to induce GFP-positively marked clones.

Other stocks used were: \textit{dlg-RNAi 4689 C2V} (gift from B. Dickson, (DIETZL et al. 2007)), validated for knockdown of Dlg and specificity (GRZESCHIK et al. 2010), \textit{msn\textsuperscript{06946}} \textit{(msn-lacZ)} (MATTILA et al. 2005); \textit{UAS-P35} (HAY et al. 1994); \textit{UAS-bsk\textsuperscript{K53R}} (\textit{UAS-bsk\textsuperscript{DN}}) (WEBER et al. 2000), \textit{UAS-aPKC\textsuperscript{AN}} (BETSCHINGER et al. 2003); \textit{UAS-aPKC\textsuperscript{CAAX-DN}} (SOTILLOS et al. 2004); \textit{UAS-Ras85D\textsubscript{V12}} (\textit{UAS-Ras\textsuperscript{ACT}}) (KARIM and RUBIN 1998); \textit{UAS-Rac1\textsuperscript{NI7}} (\textit{UAS-Rac1\textsuperscript{DN}}) (LUO et al. 1994); \textit{UAS-Rho1\textsuperscript{RNAi} #12734} (Vienna Drosophila Resource Center (VDRC), (DIETZL et al. 2007)) and \textit{scrib}\textsuperscript{1} (D. Bilder).
**Immunocytochemistry for analysis of Drosophila tissues:** For analysis of 3rd instar larval eye-antenna discs, the discs were dissected in PBS, fixed in 4% PFA, washed in PBT (0.1% TritonX-100) and blocked in PBT + 2% Normal Goat Serum. BrdU labeling for the detection of S phase cells, was carried out as previously described (LEONG et al. 2009). Antibodies used were: mouse Elav (Developmental Studies Hybridoma Bank (DSHB, 1:20), mouse β-galactosidase (Rockland, 1:500) and mouse anti-BrdU (Becton-Dickinson, 1:50). Secondary antibodies were: anti-mouse Alexa647 (Invitrogen; 1:400) or anti-mouse Alexa488 (Invitrogen; 1:400). F-actin was detected with phalloidin-tetramethylrhodamine isothiocyanate (Rhodamine; Sigma, 0.3mM).

**Matrigel invasion assay for mammalian MCF10A cells:** Parental MCF10A cell lines were retrovirally co-infected with JNK1a1, MKK4 and MKK7 overexpression constructs and H-RasV12cherry selected with puromycin, sorted for GFP/cherry on a FACSVantage SE-DiVa flow cytometer (Becton Dickinson, Franklin Lakes, NJ) and maintained as previously described (DOW et al. 2008). MCF10A derivative cell lines stably expressing candidate genes were quantified for invasive phenotypes in 3D organotypic cultures as previously described (DOW et al. 2008) using growth factor reduced Matrigel (BD Biosciences, Franklin Lakes, NJ USA) and the standard overlay method (DEBNATH et al. 2003; DOW et al. 2008). After 7 days in culture, individual acini were classified as “Normal” acini defined as those with a contiguous acini boundary with no cellular extensions, or “invasive”, being defined as acini with disorganized boundary structures showing cellular protrusions or cellular spikes invading into the surrounding matrix. Cell lines were plated in duplicate wells for each experiment and 100 acini were scored per well.

**Constructs and antibodies for mammalian cell analysis:** JNK1a1, MKK4 and MKK7 overexpression constructs were PCR amplified from Addgene plasmids 13798 (pcDNA3-Flag-JNK1a1), 14615 (pcDNA3-Flag-MKK4) and 14538 (pcDNA3-Flag-MKK7a1) and inserted into
pMSCV\textsuperscript{puro} (clontech, PT3303-5) or MSCV-IRES-GFP. MSCV-cherry-IRES-H-Ras\textsuperscript{V12} and MSCV control vectors were already available (Dow et al. 2008).

The following primary antibodies were used for probing Western blots: \(\alpha\)-tubulin (no. T5168; Sigma-Aldrich), Mouse anti-MKK7 (no. 32-7000, Invitrogen), monoclonal mouse Anti-Flag (F3165, Sigma), rabbit anti-SEK1/MKK4 (no. 9152, cell signaling), rabbit anti-Ras (cloneMC57, no. 05-775, upstate). Peroxidase labeled horse anti-mouse IgG (S1018, vector laboratories, Burlingame, CA) and goat anti-rabbit IgG (no. 170-6515, Bio-Rad laboratories, Hercules, CA) secondary antibodies were used for LiCor western blotting.

**Scanning electron microscopy and imaging:** Fluorescent labeled samples were mounted in 80% glycerol and analyzed by Confocal microscopy (Bio-Rad MRC1000 or Olympus FV1000) and images were processed using Confocal Assistant\textsuperscript{R} and Fluoview software, and images assembled using Adobe Photoshop CS2 and Adobe Illustrator CS2. Adult eyes were imaged with a Scitec Infinity1 camera. Scanning electron micrographs of adult eyes were carried out as previously described (Richardson et al. 1995), except that the samples were gold coated before imaging and were imaged on a Philips XL30 FEG Field-emission scanning electron microscope, at 2V, and working distance = 10mm.

**Breast Cancer Gene expression datasets:** Breast cancer datasets used are publicly available and were downloaded from the authors’ websites (see supplementary information). We used normalized data \((\log^2\text{intensity in single-channel platforms or log}^2\text{ratio in dual-channel platforms})\) and probe sets were mapped to Entrez-Gene IDs to merge data across the various datasets. Breast cancer subtypes were defined using a two-dimensional clustering model previously described based on two module scores, ESR1 and HER2 representing ER and HER2 phenotypes, respectively. Gene sets representing JNK and RAS signaling were combined to compute a gene signature score defined as the weighted linear
combination of the log2 expression values of the genes in the signature. Kruskal-Wallis tests were used
to determine differences in expression between classes and Spearman’s Rho correlations were used to
assess correlations between the signatures. For further information see supplementary methods.
RESULTS

A screen for RasACT-cooperating genes in the developing Drosophila eye reveals cell morphology regulators: To identify novel genes able to cooperate with activated Ras85D (RasACT), we first sought to generate a hyperplastic phenotype mediated by RasACT that could be used in an F1 screen. Expression of RasACT via the eyeless-GAL4 (ey-GAL4) driver in the developing eye has been previously shown to result in hyperplasia during larval development and generate an overgrown adult eye phenotype (Karim and Rubin 1998). Therefore, we generated a stock containing ey-GAL4 and UAS-RasACT (ey>RasACT), which resulted in overgrown adult eyes that was more obvious in males than females (Figure 1A,B). At the larval stage, the expression of RasACT led to enlarged eye discs with enlarged ommatidia and greater spacing between ommatidial clusters (Figure S3,4), consistent with the documented role of RasACT in cell growth and proliferation (Karim and Rubin 1998; Prober and Edgar 2000). To validate that the phenotype of ey>RasACT was responsive to genes known to cooperate with RasACT in tumorigenesis, we tested if knocking down the junctional neoplastic tumor suppressors, dlg, scrib or lgl, by RNAi, could enhance the phenotype. Indeed, dlg knockdown enhanced the ey>RasACT hyperplastic eye phenotype at the adult stage, and resulted in subtly larger eye discs than RasACT alone, with greater spacing between ommatidial clusters (Figure 1D, S3,4), but had no obvious defects when expressed alone (Figure 1C S3,4). lgl or scrib knockdown had only mild effects on the ey>RasACT phenotype (data not shown), perhaps due to a lower level of knockdown achieved with these RNAi lines. To determine whether the ey>RasACT adult eye phenotype was sensitive to increased activity of polarity regulators, we then tested whether overexpression of an activated version of the apical cell polarity regulator aPKC (aPKCΔN), which alone does not affect the adult eye, could enhance the ey>RasACT phenotype. Indeed ey>RasACT aPKCΔN adult females exhibited strongly enhanced hyperplastic eyes (Figure 1E,F), whereas no males eclosed (presumably reflecting the stronger phenotype of RasACT expression exhibited in males). Furthermore, overexpression of the apical cell
polarity regulator Crb, via the ey driver, resulted in an ablated eye phenotype alone, but was pupal lethal with Ras<sup>ACT</sup> (data not shown). Thus, these data show that deregulation of polarity regulators can enhance the Ras<sup>ACT</sup> phenotype, and validate the use of the ey>Ras<sup>ACT</sup> adult eye phenotype as a system suitable for screening for genes that when overexpressed can cooperate with oncogenic Ras, to increase hyperplasia or result in pupal lethality.

To identify novel genes that when over-expressed cooperate with Ras<sup>ACT</sup> we screened the GS line collection of enhancer P lines (AIGAKI et al. 2001; TOBA et al. 1999). The map position of these lines in the genome, as well as the tagged gene (the gene which is over-expressed by the line) has, in most cases, been determined and a database established to enable ready access to this information (http://gsdb.biol.metro-u.ac.jp/%7Edclust/). This enhancer P transgenic set has been successfully used in several screens to identify interacting genes (AIGAKI et al. 2001; KANUKA et al. 2005; LAVIOLETTE et al. 2005; ZHANG et al. 2006). To identify enhancers of Ras<sup>ACT</sup>, we carried out an F1 screen, scoring for lines that enhanced the mild hyperplastic phenotype of ey>Ras<sup>ACT</sup>. ~5,000 GS lines were screened and lines that scored as moderate or strong enhancers were retested against ey>Ras<sup>ACT</sup>. Confirmed interacting GS lines (Table 1 and see Table S1) were then validated by testing whether independent enhancer P lines or transgenes could also enhance the ey>Ras<sup>ACT</sup> phenotype. The interactors were also analyzed for whether they resulted in hyperplasia alone by crossing to ey-GAL4. Those that were unable to be confirmed by independent enhancer P lines or transgenes, or produced only mild enhancement with an independent line, were not pursued (see Table S1). A possible reason why some of these could not be validated by an independent transgene or enhancer P line, is that the GS line was inserted in the open-reading frame of the gene, and therefore a truncated neomorphic protein may be produced (see Table S1). Alternatively, the level of expression of the gene may be critical for cooperation with Ras<sup>ACT</sup> and the GS line may express the protein at a different level than the independent lines. An example of this is Src, which has previously been described as promoting
hyperplasia at a lower level of expression, but inducing cell death and tissue ablation when expressed at a higher level (VIDAL et al. 2007).

One validated enhancer was Delta, which is a ligand for Notch, however as has been previously described (BAONZA and FREEMAN 2005; FERRES-MARCO et al. 2006), it also showed a hyperplastic eye phenotype when expressed alone (data not shown), and was not further analyzed. Validated enhancers exhibited phenotypes ranging from eyes with regions of aberrant differentiation (cuticle and bristles within the eye field), morphological defects and male lethality at the pupal stage to enlarged, overgrown adult eyes (Table 1 and see Table S1). Strikingly, the majority of the cooperating genes fell into the category of Rho-family GTPases, Rho1 and Rac1 (SETTLEMAN 2001), and Rho1 regulators, RhoGEF2 (BARRETT et al. 1997; HACKER and PERRIMON 1998) and Pbl (PROKOPENKO et al. 1999) (see below). The other two cooperating genes were the BTB/POZ and Psq domain nuclear localized protein, Ribbon (Rib), required for cell shape changes and epithelial morphogenesis (BRADLEY and ANDREW 2001; SHIM et al. 2001), and the nuclear cytoskeletal regulator, East (WASSER and CHIA 2000) (Figure 2, Figure S1, S2).

The effects of the $Ras^{ACT}$-cooperating genes on cell survival, proliferation, differentiation and morphology: Expression of the $Ras^{ACT}$-cooperating genes alone did not result in hyperplasia, and indeed rib, Rho1 and RhoGEF2 resulted in small eyes with morphological defects, suggesting that they were inducing cell death (Figure S1, S2). Since activation of Ras inhibits apoptosis (BERGMANN et al. 1998; KURADA and WHITE 1998), it was possible that $Ras^{ACT}$ was cooperating with these genes by preventing cell death. However, expression of the cell death inhibitor, P35 (a caspase inhibitor (HAY et al. 1994)), with the $Ras^{ACT}$-cooperating did not lead to increased hyperplasia (see Figure S1, S2), although the male lethality of Rho1 was rescued by expressing $p35$ (see Figure S2). Thus, $Ras^{ACT}$ does not cooperate by simply blocking cell death, although it is possible that its cell survival function could
contribute to the cooperative effects. Therefore, Ras\textsuperscript{ACT} must be providing other functions, such as promoting cell growth and proliferation or affecting cell-cell adhesion, as has been previously reported (O'Keeffe et al. 2007; Prober and Edgar 2000; Prober and Edgar 2002), and we have observed in cooperative tumorigenesis with scrib mutants (Brumby and Richardson 2003).

As detailed below, whilst all of the Ras\textsuperscript{ACT}-cooperating genes enhanced Ras\textsuperscript{ACT} tissue growth, a spectrum of cooperative effects were observed: pbl, Rac1 and east enhanced Ras\textsuperscript{ACT} tissue growth, RhoGEF2 enhanced the effect of Ras\textsuperscript{ACT} on tissue growth, as well as affected cell morphology and differentiation and Rho1 or rib (which alone had strong morphology defects, differentiation defects and disorganized proliferation patterns) cooperated with Ras\textsuperscript{ACT} by enhancing tissue growth as well as affecting cell morphology and differentiation (see Figures S1-S4).

Rac1: The GS line and an independent transgene for Rac1 (Luo et al. 1994) showed similar hyperplastic phenotypes with Ras\textsuperscript{ACT} (Figure 2C,D). In the larval eye disc, expression of Rac1 alone did not affect eye development, however with Ras\textsuperscript{ACT} it resulted in an increased tissue growth, morphological defects, although differentiation still occurred, although aberrantly patterned (see Figures S3, S4).

Rho1: The Rho1 GS line showed a strong effect with ey\textgreater{}Ras\textsuperscript{ACT} resulting in male lethality (Figure 2E), however expression of several Rho1 transgenes did not enhance the ey\textgreater{}Ras\textsuperscript{ACT} phenotype to the same extent as the GS line, although UAS-Rho1\textsuperscript{CFP2a} (Greco et al. 2001), showed slight-moderately increased hyperplasia (see Figure S2). Expression of the Rho1 GS line alone via the ey driver led to male lethality and females had very reduced eyes with differentiation defects, but ey\textgreater{}Rho1\textsuperscript{CFP2a} did not noticeably affect the adult eye (see Figure S2). It is possible that the wild-type Rho1 transgenes tested did not express Rho1 to the same level as the GS line, and therefore could not accumulate sufficient
levels of active GTP-bound Rho to show cooperation with \textit{Ras}^{ACT}. Therefore, we tested an activated allele of \textit{Rho1}, \textit{Rho1}_{V14} (\textit{Rho1}^{ACT}) \cite{Lee_2000}. \textit{Rho1}^{ACT} alone was male lethal, but female eyes were not as severely affected as with \textit{Rho1}_{GS12503} (see Figure S2). Expression of \textit{Rho1}^{ACT} with \textit{Ras}^{ACT} strongly enhanced the \textit{ey}\\textgreater \textit{Ras}^{ACT} phenotype (Figure 2F, and see Figure S2), indicating that activated Rho was required for cooperation with \textit{Ras}^{ACT}. Consistent with the effect on the adult eyes, \textit{Rho1} or \textit{Rho1}^{ACT} alone resulted in very small eye discs, although S phases were observed throughout the eye disc, and exhibited altered cell morphology and reduced differentiation (Figures S3, S4). Co-expression of \textit{Ras}^{ACT} with \textit{Rho1} or \textit{Rho1}^{ACT} resulted in larger eye discs relative to these genes alone, however proliferation and differentiation were similarly affected (see Figures S3, S4).

\textit{RhoGEF2}: The \textit{GS} line targeting \textit{RhoGEF2} and an independent \textit{RhoGEF2} transgene \cite{Mulinari_2008} cooperated with \textit{ey}\\textgreater \textit{Ras}^{ACT} (Figure 2G,H, and see Figure S2). However, the \textit{RhoGEF2} transgene showed more severe effects than the \textit{GS} line, resulting in greater hyperplasia in females and male lethality at the pupal stage (Figure 2H; see Figure S2; and data not shown). When expressed alone the \textit{RhoGEF2} transgene was also more severe than the \textit{GS} line, resulting in ablation of eye tissue (Figure S2). Consistent with these effects on the adult eye, in the larval eye discs \textit{RhoGEF2} alone resulted in aberrant proliferation patterns and tissue morphology (see Figure S3), and partially blocked differentiation (see Figure S4), and when expressed with \textit{Ras}^{ACT} strongly affected tissue morphology and blocked differentiation (see Figure S4).

\textit{Pbl}: \textit{GS} lines targeting \textit{pbl}, and two out of five independent \textit{pbl} transgenes \cite{Somers_2003} enhanced the \textit{ey}\\textgreater \textit{Ras}^{ACT} phenotype (Figure 2I,J, and see Figure S2; and data not shown). Of the independent transgenes, \textit{UAS-pbl}^{GFP\#8} showed a stronger effect than \textit{UAS-pbl}^{GFP\#3} (data not shown). Although we have not tested it directly, it is possible that the level of \textit{pbl} expression is critical for the cooperative effects with \textit{Ras}^{ACT}. In the larval eye disc, expression of \textit{pbl} alone did not prevent
differentiation nor did it substantially affect the pattern of S phases or tissue morphology (see Figure S3, 4). Co-expression of \( \text{Ras}^{ACT} \) with \( pbl \) resulted in an enhancement of the tissue growth effect of \( \text{Ras}^{ACT} \), as well as morphological defects, although differentiation still occurred, albeit in an aberrant pattern (see Figure S3, S4).

**Rib**: An independent transgene of \( \text{rib} \) (Bradley and Andrew 2001) resulted in a more extreme phenotype than the \( \text{GS} \) line with \( \text{ey}^{>\text{Ras}^{ACT}} \), since it was lethal in both males and females (data not shown). Expression of \( \text{rib} \) \( \text{GS} \) line alone via the \( \text{ey} \) driver, resulted in reduced adult eyes with differentiation defects in both males and females (see Figure S1), whilst the \( \text{rib} \) transgene was male and female lethal when expressed with \( \text{ey-GAL4} \). Consistent with the adult phenotypes, expression of \( \text{rib} \) alone resulted in very small eye discs, although S phases were observed throughout the eye disc, that had altered cell morphology and reduced differentiation (see Figure S3, S4). Co-expression of \( \text{Ras}^{ACT} \) with \( \text{rib} \) resulted in larger eye discs relative to \( \text{rib} \) expression alone, however proliferation and differentiation were similarly affected (see Figure S3, S4).

**East**: The cooperation of \( \text{east} \) with \( \text{Ras}^{ACT} \) was confirmed by expression of a \( \text{UAS-east} \) transgene (Wasser and Chia 2000) (Figure 2L,M). In larval eye discs, expression of \( \text{east} \) alone did not prevent differentiation (see Figure S4), nor obviously affect the pattern of S phases or tissue morphology (see Figure S3), but with \( \text{Ras}^{ACT} \) it enhanced the tissue growth effect of \( \text{Ras}^{ACT} \) and led to morphological and differentiation defects (see Figure S3, S4).

**The requirement of \( \text{Rac} \) or \( \text{Rho}1 \) activity for cooperation with \( \text{Ras}^{ACT} \)**: Since \( pbl \) and RhoGEF2 are known actin cytoskeletal regulators that function through the Rho-family GTPase, \( \text{Rho}1 \) (Hacker and Perrimon 1998; O'Keeffe et al. 2001; Padash Barmchi et al. 2005; Patch et al. 2009), we reasoned that other \( \text{Ras}^{ACT} \)-cooperating genes may work in a common pathway via \( \text{Rho}1 \) or \( \text{Rac}1 \) in their
cooperation with Ras$^{ACT}$. To address this, we assessed the requirement of Rho1 or Rac1 on the ability of the Ras$^{ACT}$-cooperating genes for the cooperation with Ras$^{ACT}$ in a whole tissue setting. To block Rac1 function we expressed a dominant negative allele, blocked in the inactive GDP-bound state, Rac1$^{N17}$ (Rac1$^{DN}$) (LUO et al. 1994). There are three Rac genes in Drosophila that have overlapping functions and it is likely that the Rac1 dominant negative allele interferes with the function of all Rac genes (HAKEDA-SUZUKI et al. 2002). To reduce Rho1 function, we used a RNAi transgene (Rho1$^{RNAi}$), which has been shown to effectively knockdown Rho1 protein levels and function (MASSARWA et al. 2009; YAN et al. 2009). Whilst expression of Rac1$^{DN}$ or Rho1$^{RNAi}$ showed no discernable effects alone (data not shown) or on the ey$^{>}$Ras$^{ACT}$ phenotype (see Figure S5), Rac1$^{DN}$ suppressed the cooperation with Rac1 and Ras$^{ACT}$, and Rho1$^{RNAi}$ suppressed Rho1$^{GS12503}$ and Rho1$^{ACT}$ cooperation with Ras$^{ACT}$, as expected (Table 2; see Figure S6). Both Rac1$^{DN}$ and Rho1$^{RNAi}$ showed suppression of the ey$^{>}$Ras$^{ACT}$ dlg$^{RNAi}$ and ey$^{>}$Ras$^{ACT}$ aPKC$^{DN}$ phenotypes (Table 2; see Figure S5). Rho$^{RNAi}$ suppressed RhoGEF2 and pbl cooperation with Ras$^{ACT}$ (Table 2; see Figure S7), as expected. Interestingly, Rac1$^{DN}$ suppressed pbl, and showed partial suppression of RhoGEF2 cooperation with ey$^{>}$Ras$^{ACT}$, but did not alter the ability of Rho1$^{GS12503}$, Rho1$^{ACT}$, rib or east, to cooperate with Ras$^{ACT}$ (Table 2; see Figures S6, S7). Rho$^{RNAi}$ partially suppressed rib$^{GS9641}$ (although not the stronger rib transgene, data not shown), but not Rac1 or east (Table 2; see Figures S6, S7). Collectively, these genetic interactions are consistent with the notion that Dlg, aPKC, RhoGEF2 and Pbl act upstream of Rho1 and Rac in their cooperative effects with Ras$^{ACT}$. These results also suggest that in their cooperation with Ras$^{ACT}$, Rib acts upstream of Rho1 and East acts downstream or independently of Rho1 and Rac.

**The requirement of aPKC activity for the cooperation with Ras$^{ACT}$**: Since we have previously shown that the scrib mutant clonal phenotype depends on aPKC and that aPKC contributes to the cooperative tumorigenesis of scrib mutants with Ras$^{ACT}$ or Notch$^{ACT}$ (LEONG et al. 2009), we tested whether the Ras$^{ACT}$-cooperating genes also required aPKC for their cooperative effects. We blocked
aPKC activity by expression of a kinase-dead (dominant negative) transgene (aPKC<sup>DN</sup>) (Sotillos et al. 2004), which in clones can suppress the defects of scrib or lgl mutants (Grzeschik et al. 2007; Leong et al. 2009). aPKC<sup>DN</sup> exhibited no effect upon the ey>Ras<sup>ACT</sup> phenotype (see Figure S5), however it partially suppressed the cooperative effect of dlg<sup>RNAi</sup> with Ras<sup>ACT</sup> (Table 2, see Figure S5), consistent with the antagonistic relationship between these proteins (see Introduction). Surprisingly, aPKC<sup>DN</sup> did not suppress the ey>Ras<sup>ACT</sup> aPKC<sup>ΔN</sup> phenotype (Table 2, see Figure S5), perhaps due to high expression of aPKC<sup>ΔN</sup>, although it can suppress weaker activated aPKC phenotypes due to expression of a membrane-tethered aPKC construct (aPKC<sup>CAAX-WT</sup> (Sotillos et al. 2004); and data not shown). aPKC<sup>DN</sup> was unable to suppress the cooperative effects of any of the other Ras<sup>ACT</sup>-cooperating genes (Table 2; see Figures S6, S7), suggesting that aPKC acts upstream or independently of these genes.

**JNK is upregulated and is required for the cooperative effect of Rho-GTPases and Rho-family regulators with Ras<sup>ACT</sup>:** Activation of JNK is critical for cooperative tumorigenesis of scrib mutants with Ras<sup>ACT</sup> or Notch<sup>ACT</sup> (Leong et al. 2009). To determine the involvement of JNK signaling in the cooperation of ey>Ras<sup>ACT</sup> with RhoGEF2 and Rac1, we first tested whether JNK activity was increased in these eye discs, using the msn-lacZ reporter to monitor JNK pathway activity (Mattila et al. 2005). Expression of Ras<sup>ACT</sup> via ey resulted in a weak induction of msn-lacZ in some cells in the eye disc (Figure 3A,B), which was expected due to previous findings on the regulation of Jun and Fos activity via the Ras-MAPK signaling pathway (Ciapponi et al. 2001; Kockel et al. 1997). However, co-expression of Rac1 or RhoGEF2 with Ras<sup>ACT</sup>, resulted in a more consistent and stronger upregulation of msn-lacZ throughout the eye disc (Figure 3C,D). Thus, in the ey>Ras<sup>ACT</sup> system, JNK activity is induced by Rac1 or RhoGEF2 expression.

We then tested if blocking JNK signaling, by expression of kinase-dead (dominant negative) transgene (bsk<sup>DN</sup>), could affect the cooperation of the Ras<sup>ACT</sup>-cooperating genes with Ras<sup>ACT</sup> on the adult eye.
phenotypes. As expected based on our findings in the clonal setting (Leong et al. 2009), $bsk^{DN}$ strongly suppressed the cooperation of $Ras^{ACT}$ with $dlg^{RNAi}$ or $aPKC^{cdN}$, but did not affect the $ey>Ras^{ACT}$ phenotype (Table 2; see Figure S5). Expression of $bsk^{DN}$ also suppressed the cooperation of $RhoGEF2$, $pbl$, $Rac1$ and $Rho1^{ACT}$ and partially suppressed the stronger phenotype of $Rho1^{GSI12503}$ with $Ras^{ACT}$ (Table 2, see Figures S6, S7). Consistent with this, expression of $bsk^{DN}$ resulted in a suppression of the ectopic S phases observed in posterior region of $ey>Ras^{ACT} + Rac1$ or $RhoGEF2$ eye discs (Figure 3E-H). Thus, in the $ey>Ras^{ACT}$ system, JNK activity is required for the increased proliferation observed in $Rac1$ or $RhoGEF2 + Ras^{ACT}$ eye discs. However, $bsk^{DN}$ failed to suppress the cooperative effects of $east$ or $rib$ with $Ras^{ACT}$ (Table 2; see Figures S6, S7). Since it is conceivable that $bsk^{DN}$ could function by acting on other MAPK-family signaling pathways, such as p38, to confirm that these interactions were due specifically to blocking the JNK signaling pathway, we also tested whether reducing the dosage of $bsk$ would suppress the $ey>Ras^{ACT} + RhoGEF2$ or $Rac1$ phenotypes. Indeed, $bsk^{2/+}$ suppressed the cooperative overgrowth phenotypes of $Rac1$ or $RhoGEF2$ with $Ras^{ACT}$ (see Figure S8). Collectively, these data suggest that $RhoGEF2$, $pbl$, $Rac1$ and $Rho1$ require JNK activity for their cooperation with $Ras^{ACT}$, but that $east$ and $rib$ cooperate with $Ras^{ACT}$ independently of JNK.

Finally, to determine whether upregulation of JNK signaling was sufficient for cooperation with $Ras^{ACT}$, we co-expressed $Ras^{ACT}$ (via the $ey$ driver) with various transgenes encoding components of the JNK signaling pathway (Stronach 2005); Bsk (JNK), Hep (JNK kinase), Hep$^{ACT}$ (activated version of Hep), Msn (JNK kinase kinase kinase) and Eiger (Tumor necrosis factor (TNF) homolog, which signals through the JNK pathway). We also knocked down a negative regulator of the pathway, the JNK phosphatase, Puc (using $UAS-puc^{RNAi}$), in the $ey>Ras^{ACT}$ background. Expression of these transgenes or RNAi had no discernable effect when expressed alone (data not shown), nor did they enhance the $ey>Ras^{ACT}$ phenotype (see Figure S8; and data not shown). Thus, JNK signaling is required, but is not sufficient, for the cooperation with $Ras^{ACT}$ in the whole eye tissue setting.
In a clonal setting, Rac1, Rho1\(^{ACT}\), RhoGEF2 and pbl cooperate with Ras\(^{ACT}\) in tumorigenesis:

Mutations in genes, such as scrib, that affect cell morphology, result in tumors when the whole tissue is mutant, but are unable to do so when mutant cells are generated in clones surrounded by wild-type tissue (Brumby and Richardson 2003; Pagliarini and Xu 2003). This phenomenon is due to induction of cell-competitive mechanisms leading to JNK-mediated cell death (Adachi-Yamada and O'Connor 2004; Igaki 2009; Johnston 2009). However, while Ras\(^{ACT}\) itself in clones results in some hyperplasia and ectopic differentiation in the eye field relative to wild type (Figure 4A-D), when it is expressed in scrib\(^{-}\) clones in the eye disc, mutant clones out-grow the wild-type tissue forming massive neoplastic tumors that invade between the brain lobes (Brumby and Richardson 2003; Leong et al. 2009; Pagliarini and Xu 2003). Based on these findings, we wished to test whether the ey\(\gg\)Ras\(^{ACT}\) cooperating genes could cooperate with Ras\(^{ACT}\) in a clonal setting.

Rac1: When expressed alone, Rac1 showed many small clones that were basally excluded with pyknotic features, suggesting that cells were dying or being out-competed (see Figure S9). Rac1 cooperated with Ras\(^{ACT}\) to form large neoplastic tumors, particularly in the basal sections, and differentiation was largely blocked (Figure 4E,F). Larvae harboring these tumors showed an extended larval lifetime, over which the tumors continued to grow, reaching massive sizes, similar to scrib\(^{-}\) + Ras\(^{ACT}\) tumors (see Figure S10).

Rho1: Rho1\(^{GS12503}\) expression resulted in very small clones, suggesting that they were dying or being out-competed, however co-expression of Ras\(^{ACT}\) with Rho1\(^{GS12503}\) did not improve clonal survival (Figure S11). Since activated Rho1 (Rho1\(^{ACT}\)) was able to cooperate better than wild-type Rho1 when expressed in the whole eye tissue (Figure 2D,E), we envisaged that Rho1\(^{ACT}\) may be able to cooperate with Ras\(^{ACT}\) in clones. Indeed, while Rho1\(^{ACT}\) alone resulted in small clones and morphological defects,
\(Rho^{ACT} + Ras^{ACT}\) tumors showed overgrowth during the extended larval life-time forming invasive tumors, as scored by invasion between the brain lobes (see Figure S12).

*RhoGEF2*: Expression of *RhoGEF2* alone, resulted in small clones exhibiting features of dying cells (see Figure S9). *RhoGEF2* cooperated with *Ras\(^{ACT}\)* to form large neoplastic tumors, particularly in the basal sections, with reduced differentiation (Figure 4G-H), and the tumors increased in size over the extended larval lifespan, although were not as large as *scrib* + *Ras\(^{ACT}\)* tumors (see Figure S10).

*Pbl*: Expression of *pbl* alone produced wild-type sized clones, although some basally extruded differentiated cells were observed (see Figure S9). Similar to *RhoGEF2* + *Ras\(^{ACT}\)*, *pbl* cooperated with *Ras\(^{ACT}\)* to form large neoplastic tumors, with reduced differentiation (Figure 4I-J) and showed massive overgrowth over the extended larval stage (Figure S10).

*Rib*: *rib* expression via the transgene of *GS* line resulted in very small clones, suggesting that they were dying or being out-competed (see Figure S11; data not shown). Co-expression of *Ras\(^{ACT}\)* with *rib* mildly increased *rib* clonal size, but did not lead to tumor formation (see Figure S11). Interestingly, *rib* + *Ras\(^{ACT}\)* eye discs showed non-cell autonomous overgrowth effects, suggesting that *Ras\(^{ACT}\)* may impart “un-dead” cell characteristics to the *rib*-expressing cells, allowing the release of morphogens that promote compensatory proliferation of the surrounding wild-type tissue, as has been previously described (reviewed by Fan and Bergmann 2008).

*East*: *east*-expressing clones alone in the eye disc did not appear to show any morphological or differentiation abnormalities and co-expression of *east* with *Ras\(^{ACT}\)* resulted in a similar phenotype to *Ras\(^{ACT}\)* alone (see Figure S11). Thus, unlike the situation in the whole eye disc, East did not cooperate with *Ras\(^{ACT}\)* to promote hyperplasia or neoplasia in the clonal system.
Taken together, these data show that Rac1, an activated allele of Rho1 (Rho1ACT), RhoGEF2 and pbl, but not Rho1, rib or east, were capable of cooperating with RasACT in a clonal setting. The differences observed between cooperative effects of these genes in the whole tissue versus the clonal setting, highlight the context dependent nature of RasACT-mediated cooperative tumorigenesis.

JNK is upregulated in eye disc clones of RasACT + Rac1 or RhoGEF2, and is required and sufficient for cooperative neoplastic overgrowth: We then tested whether the JNK pathway was upregulated in eye disc clones upon the expression of Rac1 or RhoGEF2 with RasACT by monitoring the expression JNK pathway reporter, msn-lacZ. In RasACT + Rac1 or RhoGEF2 + RasACT-expressing clones, in either apical or basal sections, high levels of JNK signaling were observed (Figure 5B-D, F,G) compared with RasACT-expressing clones alone (Figure 5A) or wild-type discs (see Figure 3A). Indeed, in RasACT + Rac1-expressing clones, high levels of msn-lacZ expression was also observed in the tissue invading between the brain lobes (Figure 5D), consistent with a role for JNK in promoting cell migration and invasion. The increased expression of msn-lacZ in the RhoGEF2 + RasACT expressing clones (Figure 5F,G) compared with RasACT clones alone, likely reflected increased levels of JNK activation due to RhoGEF2 activity, since expression of RhoGEF2 alone in clones also exhibited an upregulation of msn-lacZ expression (Figure 5E). This is likely to also be the case for Rac1, although we were unable to analyze the expression of msn-lacZ in clones expressing Rac1 alone, since in this genetic background the clones were poorly viable (data not shown).

To determine the importance of JNK on the cooperative overgrowth in the clonal setting, we blocked the JNK pathway, using bskDN, in Rac1 + RasACT or RhoGEF2 + RasACT-expressing clones (Figure 6). Indeed, expression of bskDN increased differentiation and restored pupation of both Rac1 + RasACT (Figure 6C,D compared with 6A,B) and RhoGEF2 + RasACT (Figure 6G,H compared with 6E,F)
expressing clones. Furthermore, $bsk^{DN}$ reduced the invasive cell morphology of $Rac1 + Ras^{ACT}$ expressing clones and decreased the invasive properties of the tumor (Figure 6C,D compared with 6A,B; and data not shown). Furthermore, the expression of $bsk^{DN}$ in $Rho1^{ACT} + Ras^{ACT}$-expressing clones also restored pupation, increased differentiation and prevented invasion between the brain lobes (see Figure S13). Collectively, these data show that the activation of JNK is essential to prevent differentiation, to block pupation and for the invasive behavior of $RhoGEF2 + Ras^{ACT}$, $Rac1 + Ras^{ACT}$ or $Rho1^{ACT} + Ras^{ACT}$ tumors. However, at least in the case of $Rac1 + Ras^{ACT} + bsk^{DN}$ the tumors were still larger than $Ras^{ACT}$ clones alone. These data indicate that in $Rac1 + Ras^{ACT}$ tumors a JNK-independent signal appears to drive additional overgrowth. This is in contrast to the whole tissue system where the increased proliferation of $Rac1 + Ras^{ACT}$ eye discs was JNK dependent (Figure 3E,F). $RhoGEF2 + Ras^{ACT} + bsk^{DN}$ or $Rho1^{ACT} + Ras^{ACT} + bsk^{DN}$ tumors were more similar to $Ras^{ACT}$ alone, so in these cases (and possibly also $Rac1 + Ras^{ACT}$ tumors) a JNK-dependent signal is required for additional overgrowth. The requirement for JNK in this additional overgrowth is likely to relate to JNKs ability to block differentiation and pupation in these $Ras^{ACT}$-expressing clones, thereby enabling tumor overgrowth during an extended larval phase (see Discussion).

Finally, to examine whether activation of JNK was sufficient to cooperate with $Ras^{ACT}$ in a clonal setting, we expressed a $UAS-bsk$ transgene alone or in combination with $UAS-Ras^{ACT}$ in eye disc clones, and analyzed clonal growth with time (see Figure S14). Expression of $bsk$ alone in clones resulted in small clone size and many cells exhibited a pyknotic phenotype, suggesting that cells were undergoing apoptosis or being out-competed (see Figure S14). By contrast, expression of $Ras^{ACT}$ with $bsk$ rescued the cell death phenotype of $bsk$-expressing clones and at day 5 eye discs were similar to $Ras^{ACT}$ expression alone (see Figure S14). However, some $bsk + Ras^{ACT}$ mosaic larvae exhibited an extended larval phase where the tumor overgrew the surrounding wild-type tissue (see Figure S14). The tissue overgrowth was associated with altered cell morphology and aberrant differentiation.
Moreover, in older larvae, tumor invasion was observed between the brain lobes (Figure S14). Collectively, our data shows that in a clonal setting, activation of JNK is sufficient to block pupation, promote $Ras^{ACT}$-mediated proliferation, disrupt differentiation and induce invasive properties.

**Cooperation of Ha-Ras$^{V12}$ and JNK signaling in mammalian breast epithelial cells and in human cancer:** Given our findings of the importance of JNK signaling in Drosophila $Ras^{ACT}$-mediated cooperative tumorigenesis with actin cytoskeletal regulators, we sought to investigate the requirement of JNK signaling for cooperation with oncogenic Ras in mammalian cell models and in human cancer. In order to explore the cooperation of JNK with activated Ras, we utilized MCF10A normal breast epithelial cells grown in 3D matrigel cultures. MCF10A cells form acini in matrigel, however upon low level expression of activated Harvey-Ras (Ha-Ras$^{V12}$) the lumens become filled with cells and with the concomitant knockdown of cell polarity regulators, such as hScrib, cells form invasive clusters (Dow et al. 2008) – thus this system is a useful model to examine cooperative tumorigenesis. We established MCF10A cell populations overexpressing $JNK1a1$, and the JNK kinase genes, $MKK4$ or $MKK7$, with or without Ha-Ras$^{V12}$ and examined their behavior in matrigel (Figure 7A-C). MCF10A lines expressing $JNK1a1$, $MKK4$ or $MKK7$ alone were similar to controls, while low level Ha-Ras$^{V12}$ expression alone showed some invasive acini. Co-expression of $JNK1a1$, $MKK4$ or $MKK7$ with Ha-Ras$^{V12}$ resulted in a ~4-fold, ~3-fold and ~2.5-fold increase in invasive acini relative to Ha-Ras$^{V12}$ alone, respectively. Thus, similar to Drosophila, upregulation of JNK in mammalian epithelial cells cooperates with Ras$^{V12}$ to promote invasive properties upon normal human epithelial cells.

We also examined the effect of expressing $JNK1a1$, $MKK4$ or $MKK7$ in MCF10A cells on anchorage-independent growth (growth in soft agar; see Figure S15). Expression of these genes alone could not confer anchorage-independent growth to MCF10A cells or modify the ability of Ha-Ras$^{V12}$ to promote growth in soft agar. In 2D cultures, expression of $JNK1a1$, $MKK4$ or $MKK7$ also did not enhance the
proliferation rate alone or in combination with Ha-Ras\textsuperscript{V12}, and indeed M KK4 resulted in a decreased proliferation rate of Ha-Ras\textsuperscript{V12} expressing cells (see Figure S15). These data indicate that upregulation of JNK signaling cooperates with Ras\textsuperscript{V12} in 3D cultures to promote invasion, but does not enhance cell proliferation rates in 2D cultures or promote anchorage independent growth.

To further examine the relevance of our findings to human cancer, we investigated a gene signature related to JNK signaling (Han et al. 2002) for its association with gene expression in breast cancer using publicly available data sets (see Supplementary methods). Breast cancers are now divided in three major molecular subtypes, according to estrogen receptor and HER2 expression, for clinical and research purposes (Sorlie et al. 2001; Sorlie et al. 2003; Sotiriou et al. 2003), which are recognized to have different biological mechanisms of tumor growth and progression. We found that in the breast cancer subtype that overexpress the human epidermal growth factor receptor (HER2\textsuperscript{+}), there was a moderate and positive correlation with the JNK signature relative to the other breast cancer subtypes (HER2\textsuperscript{+} Spearman\textsuperscript{s} rho= 0.15, p<0.001; ER\textsuperscript{+}/HER2\textsuperscript{−} rho= 0.05, p=0.05; ER\textsuperscript{−}/HER2\textsuperscript{−} rho= 0.02, p=0.6; Figure 7D). As HER2 upregulation is known to activate Ras/Erk signaling (p<0.0001; Figure 7E), this observation is in agreement with our data, highlighting cooperation between Ras and JNK signaling. The association of a high JNK signature in ER\textsuperscript{+}/HER2\textsuperscript{−} ("luminal" subtype) breast cancers is also consistent with reports from previous clinical studies and xenograft models of tamoxifen resistance, which have reported a positive association with activated/phosphorylated JNK (Johnston et al. 1999; Schiff et al. 2000), though these tumors do not show high expression of the Ras signature (Figure 7E).

Whilst Ras is not an established oncogene in breast cancer, Ras pathway upregulation is recognized to be important for breast cancer growth and tumorigenesis (reviewed by Whyte et al. 2009), and our data support a link between Ras and JNK signaling in HER2\textsuperscript{+} breast cancers. Together these data support further investigation into the relationship between JNK and Ras signaling in human cancers.
DISCUSSION

In an genome-wide overexpression screen for Ras\textsuperscript{ACT}-cooperating genes in the developing eye, we have identified \textit{Rac1}, \textit{Rho1}, \textit{RhoGEF2}, \textit{pbl}, \textit{rib} and \textit{east}, which all have roles in regulation of cell morphology. We showed that in a clonal setting, which reveals the competitive ability of mutant tissue, that \textit{Rac1}, an activated allele of \textit{Rho1} (\textit{Rho1}\textsuperscript{ACT}), \textit{RhoGEF2} and \textit{pbl} exhibit cooperativity with \textit{Ras}\textsuperscript{ACT}.

Our studies reveal that JNK signaling is required for the cooperation of these genes with \textit{Ras}\textsuperscript{ACT}, however the role of JNK is gene and context dependent. In a whole tissue setting, we show that (1) expression of \textit{Rac1} + \textit{Ras}\textsuperscript{ACT} or \textit{RhoGEF2} + \textit{Ras}\textsuperscript{ACT} leads to upregulation of the JNK-Jun/Fos (AP-1) target gene, \textit{msn}, (2) that JNK signaling is required for the increased proliferative potential of \textit{Rac1} or \textit{RhoGEF2} with \textit{Ras}\textsuperscript{ACT}, and (3) that the eye phenotypes of \textit{Rac1}, \textit{Rho1} \textit{RhoGEF2} and \textit{pbl} require JNK, but (4) JNK is not sufficient for cooperation. By contrast in a clonal setting, upregulation of JNK is both necessary and sufficient for cooperative tumorigenesis of \textit{Rac1}, \textit{Rho1}\textsuperscript{ACT} or \textit{RhoGEF2} with \textit{Ras}\textsuperscript{ACT}: (1) JNK is upregulated in \textit{Rac1} + \textit{Ras}\textsuperscript{ACT} or \textit{RhoGEF2} +\textsuperscript{ACT} clones, (2) blocking JNK reduces the tumorigenic potential of \textit{Rac1}, \textit{RhoGEF2} or \textit{Rho1}\textsuperscript{ACT} with \textit{Ras}\textsuperscript{ACT} and (3) upregulation of JNK alone cooperates with \textit{Ras}\textsuperscript{ACT}, although was less aggressive than \textit{scrib}, \textit{Rac1}, \textit{Rho1}\textsuperscript{ACT}, \textit{RhoGEF2}, or \textit{pbl} with \textit{Ras}\textsuperscript{ACT}. This role for JNK is conserved in mammalian cells, since JNK upregulation cooperates with activated \textit{Ha-Ras} to promote invasive growth of MCF10A normal breast epithelial cells in 3D cultures, and upregulation of the JNK signature correlates with HER2\textsuperscript{+} human breast cancers, where Ras signaling is upregulated. However, upregulation of JNK signaling in mammalian cells did not increase the proliferation or anchorage-independent growth properties of \textit{Ha-Ras}\textsuperscript{V12}, consistent with our analysis that JNK was not sufficient to promote hyperproliferation in the \textit{ey-Ras}\textsuperscript{ACT} system. Collectively, our data reveals the importance of the RhoGEF/Rho-family/JNK pathway for cooperative tumorigenesis with \textit{Ras}\textsuperscript{ACT}. Moreover, our data reveals that the cooperation of JNK with oncogenic Ras in tumorigenesis is conserved between Drosophila and humans, and highlights the relevance of Drosophila screens and genetic analysis to human cancer biology.
Context dependent effects of JNK activation on cell behavior: Our analysis revealed that the $Ras^{ACT}$-cooperating genes resulted in different effects in different contexts; when expressed alone within the whole eye tissue the spectrum of phenotypes ranged from little effect ($Rac1, pbl, east$) to reduced eyes with morphological and differentiation defects ($Rho1, Rho1^{ACT}, RhoGEF2, rib$), and with $Ras^{ACT}$ from increased hyperplasia ($Rac1, pbl, east$) or more severe morphological and differentiation defects ($Rho1, Rho1^{ACT}, RhoGEF2, rib$), whilst in the clonal setting expression of the $Ras^{ACT}$-cooperating genes alone ranged from little effect ($pbl, east$) to small clones with evidence of apoptosis ($Rac1, Rho1, Rho1^{ACT}, RhoGEF2, rib$), and with $Ras^{ACT}$ either did not cooperate ($Rho1, rib$ and $east$) or resulted in neoplastic invasive tumors ($Rac1, Rho1^{ACT}, RhoGEF2, pbl$). We hypothesize that these spectrums of phenotypic outcomes are related to the severity of cell morphology disruption and to different levels of Rho1 and JNK signaling, although we have not been able to measure this directly due to the absence of reliable Drosophila reagents for Western analysis.

The reduced eye phenotype of $Rho1, Rho1^{ACT}, RhoGEF2$, and $rib$ when expressed alone in the whole eye tissue, is consistent with strong activation of JNK, since $ey$-driven expression of $hep^{ACT}$ also results in reduced eyes (data not shown). Furthermore, in cooperation with $Ras^{ACT}$ in the whole eye disc, $Rac1, Rho1, Rho1^{ACT}, RhoGEF2$ and $pbl$ required JNK. Indeed, $Rac1 + Ras^{ACT}$ and $RhoGEF2 + Ras^{ACT}$ eye discs upregulated Jun/Fos (AP-1) activity and JNK was required for the increased numbers of S phase cells in these discs. Thus, $RhoGEF2$ and $Rac1$ require the activation of JNK to cooperate with $Ras^{ACT}$ to result in increased hyperplasia. A role for JNK in promoting proliferation has recently been revealed in tissue regeneration after wounding (BERGANTINOS et al. 2010), and the SWH tissue growth control pathway has been implicated in this process (GRUSCHE et al. 2011; SUN and IRVINE 2011). Whether the SWH pathway is also required for cooperation of JNK with $Ras^{ACT}$ to increase hyperplasia remains to be determined.
In the clonal setting the cooperation of Rac1, Rho1<sup>ACT</sup>, RhoGEF2 and pbl, but not Rho1, rib or east, with Ras<sup>ACT</sup> could be related to their ability to upregulate JNK to an appropriate level. Indeed the degree of overgrowth and invasive properties may be related to the level of JNK upregulation; Rac1 + Ras<sup>ACT</sup> and scrib<sup>+</sup> + Ras<sup>ACT</sup> tumors, show a more consistent upregulation of JNK (revealed by msn-lacZ expression) than in RhoGEF2 + Ras<sup>ACT</sup> tumors, which correlates with the more severe overgrowth and invasion of Rac1 + Ras<sup>ACT</sup> or scrib<sup>+</sup> + Ras<sup>ACT</sup> tumors. Moreover, the expression of bsk (jnk) alone was sufficient to cooperate with Ras<sup>ACT</sup> to produce large neoplastic tumors, consistent with the previous report that upregulation of JNKK (Hep) expression can also cooperate with Ras<sup>ACT</sup> (Uhlirova and Bohmann 2006). Uhlirova and Bohmann also showed that the level of JNK pathway activation appears to be important for this cooperation, since overexpression of an activated version of hep (hep<sup>ACT</sup>), which in contrast to bsk or hep upregulation, promotes high levels of cell death when expressed in clones (Brumby and Richardson 2003; Leong <em>et al.</em> 2009), was unable to cooperate with Ras<sup>ACT</sup> (Uhlirova and Bohmann 2006). These observations may explain why Rho1 and rib (situations in which we hypothesize that JNK signaling may be higher), did not cooperate with Ras<sup>ACT</sup> in the clonal situation; the high levels of cell death triggered by strong JNK activation may not be able to be overcome by expression of Ras<sup>ACT</sup>. Upregulation of the Ras–MAPK signaling pathway blocks apoptosis via phosphorylation of the cell death inducer, Hid, as well as downregulation of hid transcription (Bergmann <em>et al.</em> 1998; Kurada and White 1998). When high levels of JNK activity is induced the activation of Hid or other cell death inducers may not be able to be blocked by Ras<sup>ACT</sup>. By contrast, since expression of east alone in clones did not exhibit signs of cell death, east may be unable to induce sufficient activation of JNK in the clonal setting to enable cooperation with Ras<sup>ACT</sup>.

In a clonal setting, we showed that JNK is required to block differentiation and pupation and promote the invasive phenotypes of RhoGEF2, Rac1 and Rho1<sup>ACT</sup> in cooperation with Ras<sup>ACT</sup>, although not the
cell morphology defects. The effect of JNK on invasion has been shown to be due to upregulation of targets important in cell migration, such as Paxillin, and in breakdown of the extracellular matrix, such as MMP1 (Beaucher et al. 2006; Leong et al. 2009; Srivastava et al. 2007; Uhlirova and Bohmann 2006), but how JNK blocks differentiation and pupation is currently unknown. Expression of bskDN also reduced tumor overgrowth to a level commensurate with RasACT alone for all except Rac1 + RasACT. The reduced differentiation and delayed pupation mediated by JNK most likely contributes to the overgrowth phenotypes, since the overgrowth manifests during the extended larval phase. The JNK-mediates overgrowth in these tumors may depend upon the JAK-STAT pathway, since JNK signaling in scrib− cells has been shown to induce expression of the cytokine, Unpaired (Upd), which can lead to activation of the JAK-STAT tissue growth control signaling pathway in scrib− cells, but also in adjacent cells wild-type (Wu et al. 2010). Rac1, RhotACT, RhoGEF2 and pbl + RasACT mosaic discs exhibited some non-cell autonomous tissue growth (data not shown), suggesting that such a mechanism involving JAK-STAT signaling may be occurring.

For Rac1 + RasACT + bskDN the tumors were still larger than RasACT alone, suggesting that a JNK-independent mechanism must be triggered to drive the overgrowth of these tumors and their competitive advantage over the surrounding wild-type tissue. This is similar to what occurs in scrib− + RasACT tumors when JNK signaling is blocked; although the overgrowth is reduced, tumors are still considerably larger than with RasACT alone (Leong et al. 2009). Pertinent to this, is that while activation of JNK alone can cooperate with RasACT (this study; (Uhlirova and Bohmann 2006)), the cooperative effect is not as potent as with Rac1 + RasACT or scrib− + RasACT, raising the possibility that these genes are affecting other processes to mediate cooperative overgrowth. This may include the integrity of the E-cadherin-β-catenin complex, which has been revealed to also contribute to RasACT-mediated cooperative tumourigenesis (Igaki et al. 2006). Furthermore, we and others have recently shown that the SWH pathway, which inhibits both cell proliferation and survival, is deregulated by
loss-of-function of the polarity regulator, Lgl, in the eye disc (Grzeschik et al. 2010), and in lgf + RasV12 clones in the wing disc (Menendez et al. 2010). Therefore deregulated SWH signaling could contribute to the increased proliferative potential of Rac1 + RasACT or scrib− + RasACT tumors independently of JNK. Other factors, such as the relative level of the Myc cell growth protein, which has been shown to affect the survival of lgf clones in the wing disc (Froldi et al. 2010), or the recently discovered membrane protein isoform, Flower-Lose, which is associated with dying cells in cell competition (Rhiner et al. 2010), may also be involved in the overgrowth of Rac1 + RasACT or scrib− + RasACT tumors.

Hierarchical relationships between the RasACT-cooperating genes: Our genetic analysis of the RasACT-cooperating genes with Rho1, Rac1, aPKC and bsk (jnk) in the whole eye (Table 2), has revealed an interaction relationship between these genes (Figure 8). We found that blocking aPKC, with the kinase-dead (dominant-negative) form, partially suppressed the dlgRNAi + RasACT cooperative phenotype, but not other cooperative interactions, suggesting that aPKC acts downstream of Dlg (consistent with the antagonistic relationship between basal-lateral cell polarity regulators and aPKC ((reviewed by Humbert et al. 2008)). Analysis of the genetic interactions of the RasACT-cooperating genes with JNK, revealed that JNK acts downstream of dlgRNAi, aPKCΔN, Rac1, Rho1 (and Rho1ACT), RhoGEF2 and pbl in cooperation with RasACT (Table 2, Figure 8). The cooperation of east with RasACT was epistatic to rho1, rac1, bsk and aPKC, and therefore east must act downstream or independently of these genes in its cooperation with RasACT to result in increased hyperplasia.

Analysis of the epistatic relationships of the RasACT-cooperating genes (Table 2) revealed that RhoGEF2 and pbl required both Rac1 and Rho1 activity for their cooperation with RasACT (Figure 8). The requirement for Rho1 is consistent with previous studies (Barrett et al. 1997; Hacker and Perrimon 1998; O’Keeffe et al. 2001), however the requirement of Rac1 for RhoGEF2 or Pbl function
is novel and may only be manifest in the presence of Ras$^{ACT}$. We also found that $dlg^{RNAi}$ and $aPKC^{AN}$ cooperation with Ras$^{ACT}$ required Rac1 and Rho1 function (Table 2, Figure 8), however whether their cooperation with Ras$^{ACT}$ requires RhoGEF2 or pbl remains to be determined. The mammalian homolog of Pbl (Ect2) can bind to the aPKC (PKCζ)/Par3/Par6 complex, but Ect2 was shown to regulate aPKC activity (LIU et al. 2004) rather than vice versa, as we would predict.

The cooperation of rib with Ras$^{ACT}$ was not suppressed by bsk$^{DN}$, but was suppressed by Rho1$^{RNAi}$ such that the female eyes now exhibited a hyperplastic phenotype and male lethality was rescued (Table 2). It is difficult to explain in relation to the model (Figure 8), why the rib + Ras$^{ACT}$ phenotype was suppressed by Rho1$^{RNAi}$, but not bsk$^{DN}$. It is possible that JNK is upregulated so highly by rib expression that it cannot be blocked by the bsk$^{DN}$ transgene, but the Rho1$^{RNAi}$ transgene is more effective in downregulating Rho1. The genetic interaction of rib + Ras$^{ACT}$ cooperation by Rho1$^{RNAi}$, suggests that Rho1 acts downstream of Rib to mediate cooperation with Ras$^{ACT}$. Since Rib is a nuclear-localized protein, thought to be a transcription factor (BRADLEY and ANDREW 2001; SHIM et al. 2001), it is possible that Rib may upregulate the expression of Rho1 or Rho1 regulators to mediate its known effects on epithelial migration and morphogenesis (BLAKE et al. 1998; JACK and MYETTE 1997), as well as in cooperation with Ras$^{ACT}$. Interestingly, Rib has been shown to upregulate the expression of the apical polarity regulator, Crb, and downregulate Moe (Moe) to facilitate salivary gland and tracheal tube elongation (KERMAN et al. 2008). Since Moe is a negative regulator of Rho1 (SPECK et al. 2003), upregulation of Rib would be predicted to increase Rho1 activity to mediate its affects on cell morphology. Since Rib also upregulates crb transcription (KERMAN et al. 2008), and we and others have shown that high Crb levels deregulates the SWH signaling pathway to promote tissue growth (GRZESCHIK et al. 2010; ROBINSON et al. 2010), it is possible that suppression of Rho1 activity in rib + Ras$^{ACT}$ eye discs unleashes this cryptic activity of Rib in tissue growth via its effect on Crb.
Taken together our genetic interaction data is consistent with a model whereby RhoGEF2 and Pbl act through Rho1 and Rac1 to activate JNK, and increase hyperplasia or promote morphological and differentiation defects in a whole tissue context. However, our data has revealed that while JNK is required, it is not sufficient for this cooperation with Ras\(^{ACT}\), suggesting that Rho1 or Rac1 require another unidentified factor (X or Y) for cooperation with Ras\(^{ACT}\) to promote hyperplasia or morphological and differentiation defects (Figure 8). In the case ofdlg\(^{RNAi}\), aPKC\(^{ΔN}\), pbl and Rac1 this interaction results in a hyperplastic response through JNK activation and the effector, X. By contrast, Rho1\(^{GSI2503}\) and Rho1\(^{ACT}\) result in morphological and differentiation defects via JNK activation and the Rho1 effector Y (which maybe equivalent to X), while RhoGEF2 has intermediary effects. We propose that stronger activation of Rho1 and therefore JNK in Rho1-expressing eye discs, leads to induction of a different effector, Y, or to a higher induction of effector, X. High activation of JNK could also contribute to the cell morphology changes and differentiation defects observed for Rho1, since JNK has a well-described role in cell morphology changes during Drosophila development (HARDEN 2002; MARTIN-BLANCO 1997), and has been shown to contribute to loss of apico-basal cell polarity in wing imaginal discs in lgl mutants (ZHU et al. 2010).

Whether this hierarchical pathway linking polarity regulators, through Rho1 and Rac1, to JNK activation (Figure 8) occurs in a clonal setting remains to be determined. JNK is activated in scrib\(^{-}\) clones by upregulation of Eiger (IGAKI et al. 2009), and the Drosophila macrophage-like blood cells (hemocytes) are able to recognize the mutant cells and provide the source of Eiger (CORDERO et al. 2010). However, since Rho1 and Rac1 can activate JNK during morphogenesis in Drosophila development (SETTLEMAN 2001), deregulation of cell polarity regulators may also lead to JNK activation cell intrinsically, via activation of Rho-family regulators, to contribute to Ras\(^{ACT}\)-mediated tumorigenesis. Indeed, Rho1 may directly activate JNK signaling, since it can form a complex with
Slipper (Slpr, a JNKKK) in imaginal discs to active JNK-mediated cell death (Neisch et al. 2010). Moreover, Rho1, via Rho kinase (Rok) and Myosin II (Zipper), activates JNK to mediate compensatory proliferation in imaginal discs (Warner et al. 2010). Rac1 can also activate the JNK pathway directly in dorsal closure via Slpr (Garlena et al. 2010). Whether the Ras<sup>ACT</sup>-cooperating genes lead to JNK activation in either the whole tissue or clonal context via these mechanisms remains to be determined.

**Cooperation of oncogenic Ras and JNK in mammalian cancer:** Our analysis has revealed that the importance of JNK activation for oncogenic Ras-mediated tumorigenesis extends to mammalian cells, since upregulation of JNK1a or its activators MKK4 or MKK7 cooperates with Ha-Ras<sup>V12</sup> in the MCF10A normal breast epithelial cell line, to induce invasive growth in 3D matrigel cultures. However, upregulation of the JNK signaling pathway did not cooperate with Ha-Ras<sup>V12</sup> to increase anchorage independent growth or cell proliferation in culture. Thus in this context, JNK upregulation is acting simply by promoting the invasive properties of Ha-Ras<sup>V12</sup>-expressing MCF10A cells. Our previous studies have shown that in this system, the cooperation of scrib loss-of-function with Ha-Ras<sup>V12</sup> is due to further upregulation of Ras signaling (Dow et al. 2008). Whether this is also the case for JNK pathway upregulation in cooperation with Ha-Ras<sup>V12</sup> will require further analysis.

Our analysis has also revealed a correlation of the JNK signaling signature with the HER2<sup>+</sup> breast cancer subtype, which shows upregulation of Ras signaling. This finding provides evidence that upregulation of Ras with JNK may be important for the development of certain types of human cancer. In mammalian cells and human cancer, the role of JNK signaling is complex and context dependent (Kennedy and Davis 2003; Wagner and Nebreda 2009; Weston and Davis 2007; Whitmarsh and Davis 2007). However, our experiments support previous evidence that JNK pathway activation can cooperate with oncogenic Ras in mammalian cell transformation (Ke et al. 2010; Nielsen et al. 2007; Zhang et al. 2007), therefore our analysis, together with these findings highlights the need for further
research into the association of Ras and JNK status in cancer cell lines, and the involvement of JNK signaling in Ras-dependent tumors.

Mammalian homologs exist for Pbl (Ect2), RhoGEF2 (LARG, PDZ-RhoGEF and p115-RhoGEF) and Rac1/Rho1-family proteins (Table 1). Upregulation of these proteins have been shown to induce cell transformation and are associated with human cancer (FUKUHARA et al. 2000; FUKUHARA et al. 2001; FUKUHARA et al. 1999; GOMEZ DEL PULGAR et al. 2005; MIKI et al. 1993; RIDLEY 2004; SAHAI and MARSHALL 2002; TITUS et al. 2005). Indeed, upregulation of Rho-family proteins has been shown to cooperate with oncogenic Ras in enabling cell transformation, by overcoming Ras-induced cellular senescence due to upregulation of the cell cycle inhibitor p21 (COLEMAN et al. 2004; OLSON et al. 1998). Recently, the Rac1 effector, Pak1, has been found to cooperate with ErbB2-MAPK and PI3K signaling in promoting growth factor independent proliferation in 3D cultures, and to be associated with estrogen-receptor positive human breast cancers (ARIAS-ROMERO et al. 2010). Whether JNK signaling is also involved in these cases has not been investigated. Given our findings from this study, further analysis of the association of mammalian Ect2, RhoGEF2-related proteins and Rac1/Rho1-family members with JNK signaling, in Ras-dependent human cancers is warranted. Since the Ras signaling pathway is upregulated in 30% of human cancers, but Ras itself is not sufficient for tumorigenesis due to induction of cellular senescence (COLEMAN et al. 2004; DENICOLA and TUVESON 2009; OLSON et al. 1998), our identification of the importance of JNK for cooperation of Ras with Rho-family regulators suggests new avenues of investigation in the understanding and treatment of Ras-dependent cancers.
ACKNOWLEDGMENTS

We thank Gary Hime and Hannah Robertson for coordinating the shipments of GS lines from Japan and initial discussions on the Ras\textsuperscript{ACT} genetic screen, Alyssa Harley and Peter Burke for stock maintenance and help with setting up crosses for the genetic screen, to Simon Crawford for help with the SEM, and to Linda Parsons, Nezaket Turkel, Nathalie Martinek and Karen Doggett for help with sexing larvae. We are grateful to Ben Rashleigh for developing the File Maker Pro database used for compiling data from the genetic screen, Benjamin Haibe-Kains and Izi Haviv for bioinformatic assistance. We thank Barry Dickson, Udo Hacker and Deborah Andrews for sharing prior to publication the \textit{dlg-RNAi}, \textit{UAS-RhoGEF2} and \textit{UAS-rib} flies, respectively. We also thank Robert Saint, Gary Hime, Akinao Nose, L.S. Shashidhara and the Kyoto and the Bloomington stock center for various fly stocks, and the Developmental Studies Hybridoma Bank for antibodies. We acknowledge Flybase for the wealth of information that facilitated this study. We thank Sarah Russell, members of the Richardson lab, Harvey lab and Tissue Architecture groups for discussions and helpful suggestions during the course of this research, and to Linda Parsons and Nicola Grzeschik for critique of the manuscript. This genetic screen was supported by a R21 grant from the NIH (#1R21CA098997-01), and the follow up analysis was funded in part from National Health & Medical Research (NHMRC) grants #350369 and #400211 and funds from the Peter MacCallum Cancer Center to HER, NHMRC grants to POH. HER was supported by a NHMRC Senior Research Fellowship, POH by a NHMRC Biomedical Career Development Award Fellowship, AMB was supported by funds from the NIH and NHMRC #350396 and #509051 grants, SL by a NHMRC Neil Hamilton Farley Fellowship, and PK and RG were funded by Australian Postgraduate Awards.
REFERENCES


### Table 1

**Validated eyo-Ras<sup>41L</sup>-cooperating genes, function and human homologs**

<table>
<thead>
<tr>
<th>GS line</th>
<th>Potential over-expressed genes, position of GS insertion</th>
<th>Validating transgene</th>
<th>Validated gene Function</th>
<th>Closest human homolog</th>
</tr>
</thead>
<tbody>
<tr>
<td>13019 (GSV6)</td>
<td>CG2248-RA, -2385 CG9149-RA, +2119 (antisense)</td>
<td>UAS-Rac1</td>
<td>CG2248 (Rac1) Rho-family GTPase. Actin cytoskeleton regulation.</td>
<td>Rac1 (e-101)</td>
</tr>
<tr>
<td>9792 (GSV6) 14458 (GSV6)</td>
<td>CG8114-RA, +344 (5UTR) CG8114-RA, -484</td>
<td>UAS-pbl-GFP&lt;sup&gt;3&lt;/sup&gt;</td>
<td>CG8114 (pbl) Rho family activator (RhoGEF). Actin cytoskeleton regulation, cytokinesis, migration.</td>
<td>Ect2 (e-144)</td>
</tr>
<tr>
<td>9641 (GSV6)</td>
<td>CG7230-RA, -6758</td>
<td>UAS-nib</td>
<td>CG7230 (nib) BTB/POZ transcription factor.</td>
<td>ZFP181 (e-8)</td>
</tr>
<tr>
<td>1106 (GSV1) 1211 (GSV1)</td>
<td>CG4399-RB, -163 CG4399-RB, -706</td>
<td>UAS-east</td>
<td>CG4399 (east) Metalloprotease M14 carboxypeptidase A domain and putative proteolysis activity. Nuclear endoskeleton regulation.</td>
<td>None</td>
</tr>
</tbody>
</table>
### Table 2

**Summary of genetic interactions of Rho1, Rac1, aPKC or bsk with ey-Ras<sup>act</sup> + cooperating genes**

<table>
<thead>
<tr>
<th></th>
<th>ey-Ras&lt;sup&gt;act&lt;/sup&gt;</th>
<th>ey-Ras&lt;sup&gt;act&lt;/sup&gt; Rac1&lt;sup&gt;on&lt;/sup&gt;</th>
<th>ey-Ras&lt;sup&gt;act&lt;/sup&gt; Rho1&lt;sup&gt;ten&lt;/sup&gt;</th>
<th>ey-Ras&lt;sup&gt;act&lt;/sup&gt; aPKC&lt;sup&gt;on&lt;/sup&gt;</th>
<th>ey-Ras&lt;sup&gt;act&lt;/sup&gt; bsk&lt;sup&gt;on&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>UAS-dlg&lt;sup&gt;Rho1&lt;/sup&gt;</td>
<td>enhanced</td>
<td>slight suppression</td>
<td>slight suppression</td>
<td>slight suppression</td>
<td>suppression</td>
</tr>
<tr>
<td>UAS-aPKC&lt;sup&gt;ex&lt;/sup&gt;</td>
<td>enhanced</td>
<td>suppression</td>
<td>suppression</td>
<td>no suppression</td>
<td>suppression</td>
</tr>
<tr>
<td>UAS-Rac1</td>
<td>enhanced</td>
<td>suppression</td>
<td>no suppression</td>
<td>no suppression</td>
<td>suppression</td>
</tr>
<tr>
<td>GS12503 (Rho1)</td>
<td>enhanced</td>
<td>no suppression</td>
<td>suppression</td>
<td>no suppression</td>
<td>slight suppression</td>
</tr>
<tr>
<td>UAS-Rho1&lt;sup&gt;act&lt;/sup&gt;</td>
<td>enhanced</td>
<td>no suppression</td>
<td>suppression</td>
<td>no suppression</td>
<td>suppression</td>
</tr>
<tr>
<td>UAS-RhoGEF2</td>
<td>enhanced</td>
<td>slight suppression</td>
<td>suppression</td>
<td>no suppression</td>
<td>suppression</td>
</tr>
<tr>
<td>UAS-pda&lt;sup&gt;prim&lt;/sup&gt;</td>
<td>enhanced</td>
<td>slight suppression</td>
<td>slight suppression</td>
<td>no suppression</td>
<td>suppression</td>
</tr>
<tr>
<td>GS9641 (rib)</td>
<td>enhanced</td>
<td>no suppression</td>
<td>slight suppression</td>
<td>no suppression</td>
<td>no suppression</td>
</tr>
<tr>
<td>UAS-rib</td>
<td>enhanced</td>
<td>no suppression</td>
<td>no suppression</td>
<td>no suppression</td>
<td>no suppression</td>
</tr>
<tr>
<td>UAS-east</td>
<td>enhanced</td>
<td>no suppression</td>
<td>no suppression</td>
<td>no suppression</td>
<td>no suppression</td>
</tr>
</tbody>
</table>
FIGURE LEGENDS

FIGURE 1. - Strategy for Ras<sup>ACT</sup> cooperating gene screen: Scanning electron micrographs of adult eyes (dorsal and lateral views) from female or males flies expressing oncogenic Ras (Ras<sup>ACT</sup>) and activated aPKC (aPKC<sup>ΔN</sup>) or knockdown of Dlg (dlg<sup>RNAi</sup>), compared with Ras<sup>ACT</sup> alone and controls. Posterior is to the left and dorsal is to the top in the lateral views, in this and all other adult eye figures. (A) ey-GAL4 UAS-GFP (ey>GFP), (B) ey-GAL4 UAS-Ras<sup>ACT</sup> (ey>Ras<sup>ACT</sup>), (C) ey-GAL4 UAS-dlg<sup>RNAi</sup> (ey>dlg<sup>RNAi</sup>), (D) ey-GAL4 UAS-Ras<sup>ACT</sup> UAS-dlg<sup>RNAi</sup> (ey>Ras<sup>ACT</sup> dlg<sup>RNAi</sup>), (E) ey-GAL4 UAS-aPKC<sup>ΔN</sup> (ey>aPKC<sup>ΔN</sup>). Ras<sup>ACT</sup> expression via the ey-GAL4 driver results in hyperplastic eyes. Expression of aPKC<sup>ΔN</sup> or dlg<sup>RNAi</sup> via ey-GAL4 results in slight roughening. Expression of aPKC<sup>ΔN</sup> or dlg<sup>RNAi</sup> with Ras<sup>ACT</sup> via ey-GAL4 results in enhanced overgrowth of the Ras<sup>ACT</sup> hyperplastic adult eye. Males expressing Ras<sup>ACT</sup> and aPKC<sup>ΔN</sup> die at the pupal stage. (G) Diagram of ey>Ras<sup>ACT</sup> screening strategy. ey-GAL4 UAS-Ras<sup>ACT</sup> flies were crossed to a library of enhancer P (GS) lines, expressing via UAS(GAL4) adjacent genes (UAS-gene “X”), and those which enhanced the ey>Ras<sup>ACT</sup> phenotype were selected for further analysis.

FIGURE 2. - Interaction of cooperating GS lines with ey>Ras<sup>ACT</sup> and validation: Scanning electron micrographs of adult eyes (dorsal and lateral views) from female or male flies expressing Ras<sup>ACT</sup> and cooperating GS lines or UAS transgenes via the ey driver, compared with ey>Ras<sup>ACT</sup> alone and wild-type control eyes. (A) Control (w<sup>1118</sup>), (B) ey>Ras<sup>ACT</sup>, (C) ey>Ras<sup>ACT</sup> GS13019 (Rac1), (D) ey>Ras<sup>ACT</sup> Rac1, (E) ey>Ras<sup>ACT</sup> GS12503 (Rho1), (F) ey>Ras<sup>ACT</sup> Rho1<sup>ACT</sup>, (G) ey>Ras<sup>ACT</sup> GS45 (RhoGEF2), (H) ey>Ras<sup>ACT</sup> RhoGEF2, (I) ey>Ras<sup>ACT</sup> GS14458 (pbl), (J) ey>Ras<sup>ACT</sup> pbl<sup>GFP88</sup>, (K) ey>Ras<sup>ACT</sup> GS9641 (rib), (L) ey>Ras<sup>ACT</sup> GS1211 (east), (M) ey>Ras<sup>ACT</sup> east. Expression of ey>Ras<sup>ACT</sup> with GS9641 (rib), GS12503 (Rho1) or RhoGEF2 was male lethal, and with rib was male and female lethal.
FIGURE 3. - The JNK pathway is upregulated in ey>Ras^{ACT} + Rac1 or ey>Ras^{ACT} + RhoGEF2, and blocking JNK reduces the overgrowth by decreasing the number of S phases: (A-D) LacZ staining of eye discs from female larvae of: (A) ey-GAL4 msn-lacZ, (B) ey>Ras^{ACT} msn-lacZ, (C) ey>Ras^{ACT} Rac1 msn-lacZ, (D) ey>Ras^{ACT} RhoGEF2 msn-lacZ. Rac1 or RhoGEF2 expressing eye discs show increased LacZ staining (msn expression). (E-H) BrdU labelling of eye discs from: (E) ey>Ras^{ACT} Rac1, (F) ey>Ras^{ACT} Rac1 bsk^{DN}, (G) ey>Ras^{ACT} RhoGEF2, (H) ey>Ras^{ACT} RhoGEF2 bsk^{DN}. The ectopic S phases are suppressed by blocking JNK signalling with bsk^{DN}. In E, the arrowhead marks the second mitotic wave. Scale bars = 50 μm.

FIGURE 4. - Analysis of the cooperation of Rac1, RhoGEF2 and pbl with Ras^{ACT} in eye disc clones: Expression of Ras^{ACT} with cooperating oncogenes in clones compared with controls from day 5 staged larvae stained for F-actin and ELAV. Clones are positively marked by GFP. (A) FRT82B control – apical section, (B) FRT82B control – basal section, (C) Ras^{ACT} clones – apical section, (D) Ras^{ACT} clones – basal section, (E) Ras^{ACT} + Rac1 – apical section, (F) Ras^{ACT} + Rac1 – basal section, (G) Ras^{ACT} + RhoGEF2 – apical section, (H) Ras^{ACT} + RhoGEF2 – basal section, (I) Ras^{ACT} + pbl^{GFP#3} – apical section, (J) Ras^{ACT} + pbl^{GFP#3} – basal section. In C, the arrowhead points to a patch of ectopic differentiation. Expression of Rac1, RhoGEF2 or pbl^{GFP#3} results in large overgrowths, more prominently in basal sections. Non-cell autonomous overgrowth is also observed around the clones. Scale bars = 50 μm.

FIGURE 5. - Rac1 or RhoGEF2 expression in clones results in upregulation of the JNK pathway: LacZ staining, to detect msn-lacZ expression, and F-actin staining of mosaic discs expressing Rac1 or RhoGEF2 +/- Ras^{ACT}. Clones are positively marked by GFP. (A) Ras^{ACT} clones in msn-lacZ/+ discs,
(B) Ras\textsuperscript{ACT} + Rac1 clones in msn-lacZ\textsuperscript{+} discs – apical view, (C) Ras\textsuperscript{ACT} + Rac1 clones in msn-lacZ\textsuperscript{+} discs – basal view, (D) Ras\textsuperscript{ACT} + Rac1 clones in msn-lacZ\textsuperscript{+} discs with brain lobes, showing invasion of GFP\textsuperscript{+} tissue between the brain lobes, (E) RhoGEF2 clones in msn-lacZ\textsuperscript{+} discs, (F) Ras\textsuperscript{ACT} + RhoGEF2 clones in msn-lacZ\textsuperscript{+} discs – apical view, (G) Ras\textsuperscript{ACT} + RhoGEF2 clones in msn-lacZ\textsuperscript{+} discs – basal view, BL = brain lobes. In D, the arrowhead points to GFP\textsuperscript{+} tissue invading between the brain lobes. Ras\textsuperscript{ACT} results in mild ectopic msn-lacZ expression. Ras\textsuperscript{ACT} + RhoGEF2 and Ras\textsuperscript{ACT} + Rac1 clones show extensive upregulation of msn-lacZ. In some RhoGEF2 expressing clones, high levels of msn-lacZ expression is observed. Scale bars, A-C, E-G = 50 μm, D = 200 μm.

FIGURE 6. - JNK signalling is required for cooperation of Rac1 or RhoGEF2 with Ras\textsuperscript{ACT} in clones: Clones expressing Ras\textsuperscript{ACT} with Rac1 or RhoGEF2 +/- bsk\textsuperscript{DN} at day 5, stained for F-actin and ELAV. Clones are positively marked by GFP. (A) Ras\textsuperscript{ACT} + Rac1 clones – apical view, (B) Ras\textsuperscript{ACT} + Rac1 clones – basal view, (C) Ras\textsuperscript{ACT} + Rac1 + bsk\textsuperscript{DN} clones – apical view, (D) Ras\textsuperscript{ACT} + Rac1 + bsk\textsuperscript{DN} clones – basal view, (E) Ras\textsuperscript{ACT} + RhoGEF2 clones – apical view, (F) Ras\textsuperscript{ACT} + RhoGEF2 clones – basal view, (G) Ras\textsuperscript{ACT} + RhoGEF2 + bsk\textsuperscript{DN} clones – apical view, (H) Ras\textsuperscript{ACT} + RhoGEF2 + bsk\textsuperscript{DN} clones – basal view. In B, the arrowhead points to clones with an invasive morphology. Expression of bsk\textsuperscript{DN} rescues the cooperation of Rac1 or RhoGEF2 with Ras\textsuperscript{ACT} by increasing differentiation and reducing the invasive phenotype of Rac1 + Ras\textsuperscript{ACT} clones. Scale bars = 50 μm.

FIGURE 7. - Cooperation of JNK and Ras signalling in normal mammalian epithelial cells and human cancer: (A-C) JNK1\textit{a1}, MKK4 and MKK7 cooperate with Ha-Ras\textsuperscript{V12} in promoting invasion of MCF10A cells in 3D matrigel cultures. A representative of three independent experiments with three independently derived MCF10A cell line sets overexpressing JNK1\textit{a1} (A), MKK4 (B) or MKK7 (C) in the context of Ha-Ras\textsuperscript{V12} expression is shown. Bright-field images of acini morphology (left panel)
[scale bar = 100μm]. Invasive morphology quantitation expressed relative to Ha-Ras$^{V12}$ control [*p<0.05; Students T-test, two tailed, unpaired. Error bars represent standard deviation] (right panel).

Western blot of whole-cell lysates probed with antibodies as indicated on the right side of each panel. α-tubulin was used as loading control. (D, E) Box-plots representing expression of a gene signature of JNK activation and Ras activation in human breast cancers. The relative expression of JNK signature genes (D) and Ras signature genes (E) were compared using gene expression data and divided according to the three major molecular breast cancer subtypes: ER$^-$/HER2$^-$ (triple negative), HER2$^+$ and ER$^+$/HER2$^-$ (luminal). The correlation with high JNK signature expression in HER2$^+$ and ER$^+$/HER2$^-$ is higher than in the other breast cancer subtypes, and of these the Ras signature is higher in the HER2$^+$ subtype (p<0.0001).

FIGURE 8. - Model of interactions of Ras$^{ACT}$-cooperating genes: Genetic epistasis tests reveal a possible model of how the Ras$^{ACT}$-cooperating genes may function in a pathway to lead to the upregulation of JNK in the ey-GAL4 system. Expression of Ras$^{ACT}$ alone via ey-GAL4 leads to hyperplasia. Pathways shown in black lead to increased hyperplasia, whilst those in red lead to differentiation defects and morphological changes, which we propose is due to higher levels of Rho1 and JNK signalling. Proteins shown in green are hypothesized to be required for the effects, based on information in other systems (see text). Since JNK is required, but not sufficient, to cooperate with ey$>$Ras$^{ACT}$, we hypothesize that other factors (X or Y) are altered by Rho1 or Rac1 signalling to enable cooperation with Ras$^{ACT}$. Whether knockdown of Dlg or activation of aPKC requires Pbl or RhoGEF2 is not known (indicated by ?). See text for further details.
figure 1

<table>
<thead>
<tr>
<th>males</th>
<th>females</th>
<th>males</th>
</tr>
</thead>
<tbody>
<tr>
<td>ey&gt;GFP</td>
<td>ey&gt;Ras^{ACT}</td>
<td>ey&gt;Ras^{ACT}</td>
</tr>
<tr>
<td>A</td>
<td>B</td>
<td>B'</td>
</tr>
<tr>
<td>ey&gt; dlg^{RNAi}</td>
<td>ey&gt;Ras^{ACT} dlg^{RNAi}</td>
<td>ey&gt;Ras^{ACT} dlg^{RNAi}</td>
</tr>
<tr>
<td>C</td>
<td>D</td>
<td>D'</td>
</tr>
<tr>
<td>ey&gt;aPKC^{ΔN}</td>
<td>ey&gt;Ras^{ACT} aPKC^{ΔN}</td>
<td>ey&gt;Ras^{ACT} aPKC^{ΔN}</td>
</tr>
<tr>
<td>E</td>
<td>F</td>
<td></td>
</tr>
</tbody>
</table>

G

GS line

GAL4

5' OPEN READING FRAME "X"

UAS-gene "X" x ey-GAL4 UAS-Ras^{ACT} → enhancement

LETHAL
**figure 2**

<table>
<thead>
<tr>
<th>females</th>
<th>males</th>
<th>females</th>
<th>males</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (w^{118})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{Rac1})</td>
</tr>
<tr>
<td>A</td>
<td>A'</td>
<td>B</td>
<td>B'</td>
</tr>
<tr>
<td>(\text{ey&gt;Ras}^{\text{ACT}}) GS13019 (Rac1)</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{RhoGEF2})</td>
</tr>
<tr>
<td>C</td>
<td>C'</td>
<td>D</td>
<td>D'</td>
</tr>
<tr>
<td>(\text{ey&gt;Ras}^{\text{ACT}}) GS12503 (Rho1)</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{Rho1}^{\text{ACT}})</td>
</tr>
<tr>
<td>E</td>
<td>F</td>
<td>G</td>
<td>H</td>
</tr>
<tr>
<td>(\text{ey&gt;Ras}^{\text{ACT}}) GS45 (RhoGEF2)</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{RhoGEF2})</td>
</tr>
<tr>
<td>I</td>
<td>J</td>
<td>K</td>
<td>L</td>
</tr>
<tr>
<td>(\text{ey&gt;Ras}^{\text{ACT}}) GS14458 (pbl)</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{pblGFP}^{#8})</td>
</tr>
<tr>
<td>M</td>
<td>M'</td>
<td>N</td>
<td>N'</td>
</tr>
<tr>
<td>(\text{ey&gt;Ras}^{\text{ACT}}) GS9641 (rib)</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{rib})</td>
</tr>
<tr>
<td>O</td>
<td>O'</td>
<td>P</td>
<td>P'</td>
</tr>
<tr>
<td>(\text{ey&gt;Ras}^{\text{ACT}}) GS1211 (east)</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{ey&gt;Ras}^{\text{ACT}})</td>
<td>(\text{east})</td>
</tr>
</tbody>
</table>
**figure 3**

<table>
<thead>
<tr>
<th></th>
<th>F-actin</th>
<th>LacZ</th>
<th>F-actin</th>
<th>LacZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>ey-GAL4</td>
<td></td>
<td>msn-lacZ</td>
<td>ey-RasACT</td>
<td>msn-lacZ</td>
</tr>
<tr>
<td>A</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td>A'</td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td>ey&gt;RasACT</td>
<td></td>
<td>Rac1 msn-lacZ</td>
<td>ey&gt;RasACT</td>
<td>RhoGEF2 msn-lacZ</td>
</tr>
<tr>
<td>C</td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
<td>C'</td>
<td><img src="image7.png" alt="Image" /></td>
</tr>
<tr>
<td>ey&gt;RasACT</td>
<td>Rac1</td>
<td>ey&gt;RasACT</td>
<td>Rac1</td>
<td>bskDN</td>
</tr>
<tr>
<td>E</td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
<td>E'</td>
<td><img src="image11.png" alt="Image" /></td>
</tr>
<tr>
<td>ey&gt;RasACT</td>
<td>RhoGEF2</td>
<td>ey&gt;RasACT</td>
<td>RhoGEF2</td>
<td>bskDN</td>
</tr>
<tr>
<td>G</td>
<td><img src="image13.png" alt="Image" /></td>
<td><img src="image14.png" alt="Image" /></td>
<td>G'</td>
<td><img src="image15.png" alt="Image" /></td>
</tr>
</tbody>
</table>
Figure 4

<table>
<thead>
<tr>
<th>F-actin</th>
<th>GFP</th>
<th>ELAV</th>
<th>ELAV/GFP</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>A'</td>
<td>A''</td>
<td>A'''</td>
</tr>
<tr>
<td>B</td>
<td>B'</td>
<td>B''</td>
<td>B'''</td>
</tr>
<tr>
<td>apical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>basal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RasACT</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **apical**
  - C
  - D
  - G
  - J
- **basal**
  - D
  - G
  - J

RasACT

- **apical**
  - C
  - D
  - G
  - J
- **basal**
  - D
  - G
  - J

RasACT Rac1

- **apical**
  - C
  - D
  - G
  - J
- **basal**
  - D
  - G
  - J

RasACT RhoGEF2

- **apical**
  - C
  - D
  - G
  - J
- **basal**
  - D
  - G
  - J

RasACT pB

- **apical**
  - C
  - D
  - G
  - J
- **basal**
  - D
  - G
  - J
figure 5

<table>
<thead>
<tr>
<th>F-actin</th>
<th>GFP</th>
<th>LacZ</th>
<th>GFP/LacZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>A'</td>
<td>A''</td>
<td>A'''</td>
</tr>
<tr>
<td>B</td>
<td>B'</td>
<td>B''</td>
<td>B'''</td>
</tr>
<tr>
<td>C</td>
<td>C'</td>
<td>C''</td>
<td>C'''</td>
</tr>
<tr>
<td>D</td>
<td>D'</td>
<td>D''</td>
<td>D'''</td>
</tr>
<tr>
<td>E</td>
<td>E'</td>
<td>E''</td>
<td>E'''</td>
</tr>
<tr>
<td>F</td>
<td>F'</td>
<td>F''</td>
<td>F'''</td>
</tr>
<tr>
<td>G</td>
<td>G'</td>
<td>G''</td>
<td>G'''</td>
</tr>
</tbody>
</table>

RasACT, msn-lacZ

apical brain lobes

RasACT, Rac1, msn-lacZ

apical

RhoGEF2, msn-lacZ

apical

RasACT, RhoGEF2, msn-lacZ

apical and basal
<table>
<thead>
<tr>
<th></th>
<th>F-actin</th>
<th>GFP</th>
<th>ELAV</th>
<th>GFP/ELAV</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>B</td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
<tr>
<td>C</td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
</tr>
<tr>
<td>D</td>
<td><img src="image13.png" alt="Image" /></td>
<td><img src="image14.png" alt="Image" /></td>
<td><img src="image15.png" alt="Image" /></td>
<td><img src="image16.png" alt="Image" /></td>
</tr>
<tr>
<td>E</td>
<td><img src="image17.png" alt="Image" /></td>
<td><img src="image18.png" alt="Image" /></td>
<td><img src="image19.png" alt="Image" /></td>
<td><img src="image20.png" alt="Image" /></td>
</tr>
<tr>
<td>F</td>
<td><img src="image21.png" alt="Image" /></td>
<td><img src="image22.png" alt="Image" /></td>
<td><img src="image23.png" alt="Image" /></td>
<td><img src="image24.png" alt="Image" /></td>
</tr>
<tr>
<td>G</td>
<td><img src="image25.png" alt="Image" /></td>
<td><img src="image26.png" alt="Image" /></td>
<td><img src="image27.png" alt="Image" /></td>
<td><img src="image28.png" alt="Image" /></td>
</tr>
<tr>
<td>H</td>
<td><img src="image29.png" alt="Image" /></td>
<td><img src="image30.png" alt="Image" /></td>
<td><img src="image31.png" alt="Image" /></td>
<td><img src="image32.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Figure 6**

RasACT, RhoGEF2, bskDN

Apical, Basal
RasACT

+ Dlg

aPKC

Pbl

RhoGEF2

Rho1

Slpr

ROK-MyoII

JNK + Y

Differentiation defects and morphological changes

JNK + X

Increased hyperplasia

Rac1

Slpr

Rho1

Rac1

Hyperplasia (increased proliferation, increased survival)